| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RPL13A |
| Uniprot No | P40429 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-203aa |
| 氨基酸序列 | AEVQVLVLD GRGHLLGRLA AIVAKQVLLG RKVVVVRCEG INISGNFYRN KLKYLAFLRK RMNTNPSRGP YHFRAPSRIF WRTVRGMLPH KTKRGQAALD RLKVFDGIPP PYDKKKRMVV PAALKVVRLK PTRKFAYLGR LAHEVGWKYQ AVTATLEEKR KEKAKIHYRK KKQLMRLRKQ AEKNVEKKID KYTEVLKTHG LLV |
| 预测分子量 | 23,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RPL13A重组蛋白的3篇参考文献示例(注：以下内容为模拟生成，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*RPL13A重组蛋白在炎症反应中的调控作用及机制研究*
**作者**：Smith J, et al.
**摘要**：本研究通过表达纯化RPL13A重组蛋白，揭示了其在干扰素-γ激活的炎症通路中的关键作用。实验表明，RPL13A通过结合特定mRNA调控炎症因子(如TNF-α、IL-6)的翻译，为自身免疫疾病治疗提供新靶点。
2. **文献名称**：*RPL13A重组蛋白的晶体结构解析及其核糖体功能分析*
**作者**：Wang L, et al.
**摘要**：作者利用X射线晶体学首次解析了RPL13A重组蛋白的三维结构，发现其结构域与核糖体组装及RNA结合密切相关。该研究为理解核糖体蛋白在翻译过程中的分子机制提供了结构基础。
3. **文献名称**：*靶向RPL13A重组蛋白的抗癌药物筛选及体外验证*
**作者**：Garcia R, et al.
**摘要**：通过高通量筛选结合RPL13A重组蛋白的小分子化合物，发现两种候选药物能显著抑制癌细胞增殖并诱导凋亡。研究证实RPL13A在肿瘤代谢中的潜在治疗价值。
---
如需具体文献，建议通过PubMed或Web of Science搜索关键词“RPL13A recombinant protein”获取最新研究。
**Background of Recombinant RPL13A Protein**
Recombinant RPL13A protein is a lab-generated version of the ribosomal protein L13a, encoded by the *RPL13A* gene in humans. As a component of the 60S ribosomal subunit, RPL13A plays a fundamental role in protein synthesis by contributing to ribosome assembly and translational fidelity. Beyond its canonical role in ribosome biogenesis, RPL13A has been implicated in non-ribosomal functions, including inflammation, apoptosis, and stress responses. For instance, under inflammatory conditions like interferon-γ stimulation, RPL13A can translocate from the ribosome to participate in translational silencing of specific mRNAs, acting as part of the interferon-γ-activated inhibitor of translation (GAIT) complex.
The recombinant form of RPL13A is typically produced using heterologous expression systems, such as *E. coli* or mammalian cell cultures, enabling high-yield purification for research applications. This engineered protein often includes affinity tags (e.g., His-tag, GST-tag) to facilitate isolation and detection. Its recombinant nature ensures consistency, scalability, and reduced batch-to-batch variability compared to native protein extraction.
In research, recombinant RPL13A serves as a critical tool for studying ribosome structure, protein-RNA interactions, and regulatory mechanisms in translation. It is also used to investigate diseases linked to ribosomal dysfunction, such as certain cancers, Diamond-Blackfan anemia, and autoimmune disorders. Additionally, due to its stable expression across tissues, RPL13A mRNA or protein is frequently utilized as a housekeeping gene control in gene expression studies, though debates persist about its variability under specific conditions.
Overall, recombinant RPL13A bridges basic and translational research, offering insights into both ribosomal biology and novel therapeutic targets.
×
